Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
48 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Restenosis - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Restenosis - Pipeline Review, H2 2016', provides an overview of the Restenosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Restenosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Restenosis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Restenosis - The report reviews pipeline therapeutics for Restenosis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Restenosis therapeutics and enlists all their major and minor projects - The report assesses Restenosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Restenosis Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Restenosis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Restenosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Restenosis Overview 6 Therapeutics Development 7 Pipeline Products for Restenosis - Overview 7 Pipeline Products for Restenosis - Comparative Analysis 8 Restenosis - Therapeutics under Development by Companies 9 Restenosis - Therapeutics under Investigation by Universities/Institutes 10 Restenosis - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Restenosis - Products under Development by Companies 13 Restenosis - Products under Investigation by Universities/Institutes 14 Restenosis - Companies Involved in Therapeutics Development 15 Bio3 Research S.r.l 15 CytoTools AG 16 XBiotech Inc 17 Restenosis - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Combination Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 (connective tissue growth factor + insulin human) - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 alendronate sodium - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 Antibodies to Antagonize HMGB-1 for Cardiovascular Diseases - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 CV-18C3 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 didox - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 HMW-02Ak - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 HMW-02Ap - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 HO-3867 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 TW-01 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Restenosis - Dormant Projects 41 Restenosis - Discontinued Products 43 Restenosis - Product Development Milestones 44 Featured News & Press Releases 44 Jan 03, 2013: XBiotech Receives Fast Track Designation From FDA For True Human Monoclonal Antibody Therapy Targeting Inflammatory Cytokine IL-1a For Restenosis 44 Nov 20, 2012: XBiotech Reports Positive Phase II Interim Analysis Results Of MABp1 In Vascular Disease 44 Aug 18, 2011: XBiotech Announces Initiation Of Restenosis Clinical Trial In All Five US Sites 45 Dec 22, 2010: XBiotech Files IND For CV-18C3 Monoclonal Antibody Therapy To Treat Peripheral Vascular Disease 46 Appendix 47 Methodology 47 Coverage 47 Secondary Research 47 Primary Research 47 Expert Panel Validation 47 Contact Us 47 Disclaimer 48
List of Tables
Number of Products under Development for Restenosis, H2 2016 7 Number of Products under Development for Restenosis - Comparative Analysis, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Number of Products under Investigation by Universities/Institutes, H2 2016 10 Comparative Analysis by Clinical Stage Development, H2 2016 11 Comparative Analysis by Early Stage Development, H2 2016 12 Products under Development by Companies, H2 2016 13 Products under Investigation by Universities/Institutes, H2 2016 14 Restenosis - Pipeline by Bio3 Research S.r.l, H2 2016 15 Restenosis - Pipeline by CytoTools AG, H2 2016 16 Restenosis - Pipeline by XBiotech Inc, H2 2016 17 Assessment by Monotherapy Products, H2 2016 18 Assessment by Combination Products, H2 2016 19 Number of Products by Stage and Target, H2 2016 21 Number of Products by Stage and Mechanism of Action, H2 2016 23 Number of Products by Stage and Route of Administration, H2 2016 25 Number of Products by Stage and Molecule Type, H2 2016 27 Restenosis - Dormant Projects, H2 2016 41 Restenosis - Dormant Projects (Contd..1), H2 2016 42 Restenosis - Discontinued Products, H2 2016 43
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
